A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD- Leuprolide Acetate) in Combination With TAXOTERE (Docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients With Prostate Cancer at High Risk of Relapse After Radical Prostatectomy.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Docetaxel; Leuprorelin
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- 04 Jun 2013 Results assessing testosterone recovery presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
- 26 Jan 2012 Biomarkers information updated